Headline : Ozempic v. Mounjaro? Theres a clear winner for weight loss, study finds.

Read more from the original article on here at www.yahoo.com.

---

No. of Paragraph 39

\n \n \n '.concat(e.i18n.t("search.voice.recognition_retry"),'\n

People lost substantially more weight when they took Eli Lilly's diabetes drug Mounjaro than Novo Nordisk's Ozempic, with roughly the same side effects, drop-out rate and benefit for diabetes, according to the first major head-to-head study.

Both drugs are in the same class, known as GLP-1s, but Lilly's drug, tirzepatide, sold under the brand names Mounjaro for diabetes and Zepbound for weight loss, includes a second action that seems to boost its effectiveness. Separate studies had suggested tirzepatide led to more weight loss than semaglutide, which Novo Nordisk sells as Ozempic, for diabetes and, Wegovy, at a higher dose, for weight loss.

The new study, published Monday in JAMA Internal Medicine, compared data on more than 18,000 patients who began taking one of the two medications between May 2022 and September 2023. The study relied on electronic health records from Truveta, a collective of health systems across the country with access to data on more than 100 million patients.

Read more from the original article on here at www.yahoo.com.

Related Headlines : Ozempic v. Mounjaro? Theres a clear winner for weight loss, study finds. (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.